FINWIRES · TerminalLIVE
FINWIRES

Trident Intersects Best Drill Results to Date at Contact Lake Project in Saskatchewan

作者

-- Trident Resources (ROCK.V) intersected its best drill result to date at the Contact Lake gold project in Saskatchewan, the company said Wednesday.

Trident drilled 15.11 grams per tonne (g/t) gold over 51.83 meters in hole CL26036, representing" a rare, high-grade result in Canadian gold exploration," the company said.

The company also reported high-grade gold values from a broad zone of variably sheared host rocks within and adjacent to the Bakos Shear Zone. Other results include 5.07 g/t gold over 21.50 meters.

"What makes these results particularly compelling is the fact that mineralization remains open in all directions, highlighting the significant growth potential we see across the system," Chief Executive Officer Jon Wiesblatt said.

"We are seeing high-grade gold associated with multiple, parallel shear zones in drilling which is exciting as the potential convergence of these zones at depth represents an untested high-priority drill target," Wiesblatt added.

An additional 15 drill holes are pending from Contact Lake, targeting the high-grade BK3 zone. The company also plans to conduct drill programs in summer and fall.

相關文章

Australia

Ryde與VinaTaxi簽署諒解備忘錄,探索越南市場機會

Ryde集團(RYDE)週三宣布,已與VinaTaxi簽署諒解備忘錄,共同探索在越南的戰略合作機會。 該公司表示,合作探索的領域包括在VinaTaxi的計程車車隊中部署Ryde的平台,以及開發電動摩托車出行生態系統。Price: $1.20, Change: $+0.02, Percent Change: +1.61%

$RYDE
Australia

Emergent BioSolutions 簽署價值 5000 萬美元的合同,為 SAB Biotherapeutics 的領先項目提供支持

Emergent BioSolutions (EBS) 週三宣布,已與 SAB Biotherapeutics (SABS) 簽署一項價值 5000 萬美元的多年期協議,以推進 SAB-142 的臨床開發,該藥物用於治療自身免疫性 1 型糖尿病。 根據協議,其中 3,600 萬美元的款項取決於未來的監管審批和後續里程碑的達成情況。 Emergent BioSolutions 表示,將提供符合現行良好生產規範 (cGMP) 的端到端開發和生產服務。Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS
Australia

Immunome公司提交了基於3期臨床試驗數據的Varegacestat新藥申請。

Immunome(IMNM)週三宣布,已向美國食品藥物管理局(FDA)提交了新藥申請,申請上市的藥物為varegacestat,一種用於治療成人纖維瘤的在研口服藥物。 該公司表示,此次申請基於積極的3期RINGSIDE試驗結果,結果顯示與安慰劑相比,varegacestat顯著改善了患者的無進展生存期,降低了84%的疾病進展或死亡風險,客觀緩解率達到56%。 該公司補充說,試驗的詳細數據將在2026年美國臨床腫瘤學會(ASCO)年會上發表。 Immunome股價週三下跌2.7%。Price: $23.18, Change: $-0.53, Percent Change: -2.24%

$IMNM